Skip to content
Home/Companies/Pharma/ProJect Pharmaceutics
ProJect Pharmaceutics

ProJect Pharmaceutics

Pharma·Germany·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns ProJect Pharmaceutics?

ProJect Pharmaceutics is currently owned by AFINUM Management GmbH through AFINUM IX Buyout (2021) (2021 vintage), since 2025.

Hand-verified · updated 2026-07-03

AFINUM Management GmbH
Investor
AFINUM Management GmbH
AFINUM IX Buyout (2021) · 2021 · Small-Mid Buyout

Key facts

HQGermany
SectorPharma
StatusActive
Websiteproject-pharmaceutics.com

More from AFINUM IX Buyout (2021)

Other portfolio companies in the same fund.

Fairbanks
Fairbanks
Active
SaaSNetherlands· 2026
DPS Engineering
Active
SaaSGermany· 2025
Ergon Informatik
Active
SaaSSwitzerland· 2025
sequrio
sequrio
Active
SaaSGermany· 2025
MedTech Laser Group
Active
MedTechGermany· 2024
Objektkultur Software
Objektkultur Software
Active
SaaSGermany· 2024

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track ProJect Pharmaceutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy ProJect Pharmaceutics?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on ProJect Pharmaceutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue